Welcome to the e-CCO Library!

P417: Long-term deep remission after adalimumab discontinuation in Crohn’s disease patients.
Year: 2021
Source: ECCO'21 Virtual
Authors: Melotti, L.(1);Rizzello, F.(1);Calabrese, C.(1);Dussias, N.(1);Gionchetti, P.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P417: Non-invasive assessment of liver fibrosis by transient elastography and AST to ALT ratio in patients with Crohn's disease treated with methotrexate
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Peixoto A., Silva M., Morais R., Liberal R., Gonçalves R., Lopes S., Macedo G.

Created: Wednesday, 20 February 2019, 10:36 AM
P417: Seroconversion after COVID-19 Vaccination in Inflammatory Bowel Disease Patients
Year: 2022
Source: ECCO'22
Authors: Horvath , M.(1);Csontos , Á.A.(1);Sárközi , M.(1);Cseprekal , O.(1);Szijártó , A.(1);Miheller , P.(1);
Created: Friday, 11 February 2022, 3:52 PM
P417: Ulcerative colitis: let’s talk about extent
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Vaz*, M. Eusébio, A. Antunes, P. Queirós, T. Gago, T. Belo, P. Caldeira, H. Guerreiro

Created: Friday, 22 February 2019, 9:49 AM
P418 Filgotinib decreases molecular markers of JAK1 signal transduction in Crohn’s disease: concordance with endoscopy and histopathology
Year: 2020
Source:

ECCO'20 Vienna

Authors:

W. Reinisch1, J. Brodbeck2, R. Galien3, E. Grant2, X. Hébuterne4, M. Kłopocka5, R. Petryka6, X. Roblin7, A. Serone2, C. Tasset8, O.K. Yoon2, S. Zaboli2, S. Vermeire9

Created: Thursday, 30 January 2020, 10:12 AM
P418: Development and validation of a digital health platform (IBD NutriCare) for telenutrition in patients with Inflammatory bowel disease
Year: 2022
Source: ECCO'22
Authors: Gupta, A.(1);Singh, N.(1);Madan, D.(1);Farooqui, M.(1);Singh, N.(1);Singh, M.(1);Virmani, S.(1);Verma, M.(1);Bajaj, A.(1);Markandey, M.(1);kante, B.(1);Vuyyuru, S.K.(1);Kumar, P.(1);Sahu, P.(1);Makharia, G.(1);Kedia, S.(1);Ahuja, V.(1);
Created: Friday, 11 February 2022, 3:52 PM
P418: Does capsule endoscopy impact clinical management in established Crohn’s Disease?
Year: 2021
Source: ECCO'21 Virtual
Authors: Elosua Gonzalez, A.(1);Rullan Iriarte, M.(1);Rubio Iturria, S.(2);Oquiñena Legaz, S.(2);Rodríguez Gutiérrez, C.(2);Macías Mendizábal, E.(2);Borda Martín, A.(2);Fernández-Urién Sainz, I.(2);Nantes Castillejo, Ó.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P418: Dose escalation of oral 5-aminosalicylic acid for ulcerative colitis with Mayo endoscopic subscore of one improves long-term prognosis: a one-year multicentre, open-label, randomized controlled trial.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Aoki, Y.(1)*;Fukuda, T.(1,2,3);Kiyohara, H.(1,2);Yokoyama, A.(4);Nakazawa, A.(4);Yoshimatsu, Y.(1);Sugimoto, S.(1);Nanki, K.(1);Mikami, Y.(1);Fukuhara, K.(5);Mizuno, S.(1);Sujino, T.(6);Mutaguchi, M.(6);Takabayashi, K.(6);Morohoshi, Y.(3);Hosoda, Y.(7);Ogata, H.(6);Iwao, Y.(5);Naganuma, M.(1,8);Kanai, T.(1);
Created: Friday, 14 July 2023, 11:05 AM
P418: Pharmacodynamic biomarkers demonstrate dose-dependent pharmacological activity of the IL-22Fc fusion protein UTR1147A in healthy volunteers in a phase 1a clinical trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lekkerkerker A., Harder B., Kulkarni P., Zhao R., Choi M., Noyes A., Polihrom A., Fillos D., Rae J., Danilenko D., Stefanich E., Herman A., Lu T.

Created: Wednesday, 20 February 2019, 10:36 AM
P418: Predictive factors of surgery in the course of Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

K. Agar*, M. Medhioub, S. Jardak, L. Hamzaoui, A. Khsiba, M.M. Azzouz

Created: Thursday, 21 February 2019, 9:14 AM
P418: Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

P. Higgins*1, D. Ginsburg2, K. Gilder3, K. Gilder3, B. Walsh3, B. English3, S. Turner3, P. Klassen3, S. Hanauer4, C. Barish5, B. Yacyshyn6

Created: Friday, 22 February 2019, 9:41 AM
P418: Ulcerative colitis and end-stage liver disease in children with primary sclerosing cholangitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

P. Czubkowski*, M. Wozniak, J. Pawlowska, I. Jankowska, J. Kierkus

Created: Friday, 22 February 2019, 9:49 AM
P419 Clinical effectiveness and safety of first-line biologic vedolizumab as a monotherapy or combination therapy in ulcerative colitis and Crohn’s disease patients: results from the EVOLVE study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Bressler1, A. Yarur2, U. Kopylov3, M. Bassel4, N. Brett4, C. Colby5, C. Lopez6, S. Saha7, C. Kifnidi8, C. Agboton9, S. Adsul9, D. Demuth10, M. Luo11, S. Wang11, G.J. Mantzaris12

Created: Thursday, 30 January 2020, 10:12 AM
P419: Concentrations of anti-TNF agents in non-inflamed intestinal tissue are associated with the long-term outcome of patients with Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Yoshihara T., Shinzaki S., Kawai S., Iwatani S., Yamaguchi T., Araki M., Hiyama S., Inoue T., Hayashi Y., Watabe K., Iijima H., Takehara T.

Created: Wednesday, 20 February 2019, 10:36 AM
P419: Efficacy of vedolizumab in patients with inflammatory bowel disease and failure of anti-TNF-antibodies
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

C. Höög*, M. Eberhardson, S. Almer

Created: Friday, 22 February 2019, 9:49 AM
P419: Frequency of inadequate response to anti-tumour necrosis factor therapy in patients with ulcerative colitis. Preliminary results from POLIBD study
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Pekala*, R. Filip

Created: Thursday, 21 February 2019, 9:14 AM
P419: Long-term outcome of ulcerative colitis in pediatric patients who achieved mucosal and histological healing: a real-life referral center experience
Year: 2022
Source: ECCO'22
Authors: Scarallo, L.(1);Peruggia, E.(2);Fioretti, L.(1);Renzo, S.(1);Paci, M.(1);Naldini, S.(1);Barp, J.(1);Di Paola, M.(1);Lionetti, P.(1,3);
Created: Friday, 11 February 2022, 3:52 PM
P419: Outcomes at one year after sequential use of high-dose tofacitinib following infliximab in Acute Severe Ulcerative Colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Eqbal, A.(1)*;Hilley, P.(1);Gilmore, R.(1);Li Wai Suen, C.(1);Choy, M.(1,2);De Cruz, P.(1,2);
Created: Friday, 14 July 2023, 11:05 AM
P419: Outcomes for patients with severe acute ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Shivakumar*1, R. Grant2, R. Lynch2, T. Manship3, F. Jagger3, J. Satsangi4, G. T. Ho3, N. Plevris3, C. Lees5, I. Arnott3

Created: Friday, 22 February 2019, 9:41 AM
P419: Psychological acceptability of surgery in patients with ulcerative colitis after total colectomy
Year: 2021
Source: ECCO'21 Virtual
Authors: Itabashi, M.(1);Hirano, Y.(2,3);Saito, T.(4,5);Inoue, M.(6);Uchida, K.(6);Arai, K.(3);Minakuchi, E.(2);Ishihara, H.(2);Onizawa, R.(2);Hirayama, A.(2);Araki, K.(2);Kimura, H.(2);Kunisaki, R.(2);
Created: Wednesday, 2 June 2021, 4:12 PM